Ajinomoto Co., Inc. · TSE:2802
Ajinomoto — Merger or Acquisition (October 2015)
17 slides from Ajinomoto's merger presentation, Oct 15, 2015
Slide 1: Integration of Eisai's Gastrointestinal Disease Business and Ajinomoto Pharmaceuticals
Integration of Eisai’s Gastrointestinal Disease Business and AJINOMOTO PHARMACEUTICALS -Aiming to become Japan’s Largest Gastrointestinal Specialty Pharma- October 15, 2015 Eisai Co., Ltd. Ajinomoto Co., Inc.
Slide 2: Forward-Looking Statements and Risk Factors
Forward-Looking Statements and Risk Factors Any numerical targets contained in these materials represent medium-term strategies, future direction and vision, and are not official business forecasts. For official business forecasts, please refer to the upcoming financial results disclosure based on
Slide 3: Agenda
Agenda I. About the new integrated company 1. Aiming to become Japan’s largest gastrointestinal specialty pharma 2. Scheme and outline of the new integrated company 3. Purpose of integration 4. Product lineup of EA Pharma Co., Ltd. (“EA Pharma”) 5. Pipeline of EA Pharma 6. Synergies of integration I
Slide 4: Aiming to become Japan's largest gastrointestinal specialty pharma
I. About the new integrated company 1. Aiming to become Japan’s largest gastrointestinal specialty pharma New integrated company EA Pharma Eisai Co., Ltd. (“Eisai”) AJINOMOTO PHARMACEUTICALS A wealth of knowledge, experience and CO., LTD. networks as well as powerful products and pipeline based on 6
Slide 5: Scheme of the new integrated company
I. About the new integrated company 2. Scheme of the new integrated company <Current situation> <From April 1, 2016 (scheduled)> Eisai Ajinomoto Co. Eisai Ajinomoto Co. 100% 60% 40% Gastrointestinal AJINOMOTO disease business PHARMACEUTICALS EA Pharma Gastrointestinal disease business ＋ PHARMACEUTIC
Slide 6: Outline of the new integrated company
I. About the new integrated company 2. Outline of the new integrated company 1. Company name: EA Pharma Co., Ltd. 2. Date of establishment: April 1, 2016 (scheduled) 3. Major shareholders: Eisai 60％, Ajinomoto Co. 40％ 4. Capital: JPY 4,650 million 5. Representatives: Chairman of the Board: Takashi N
Slide 7: Purpose of integration
I. About the new integrated company 3. Purpose of integration 1. Provide a wide range of solutions and information through a robust product lineup Leveraging a product lineup that comprehensively covers the upper and lower digestive tract as well as the liver and pancreas, provide a wide range of so
Slide 8: Product Lineup of EA Pharma
I. About the new integrated company 4. Product Lineup of EA Pharma A product lineup that comprehensively covers the upper and lower digestive tract, liver and pancreas at multiple stages Esophagus, stomach, duodenum Liver, pancreas Small/large intestine Pariet® LIVACT® Proton pump inhibitor Branched
Slide 9: Pipeline of EA Pharma
I. About the new integrated company 5. Pipeline of EA Pharma Consistent launch of innovative new medicines in the field of gastrointestinal disease Phase I Phase II Phase III Upper E3810 (rabeprazole) digestive Other gastrointestinal disease pipeline products* Refractory reflux esophagitis tract mai
Slide 10: Synergies of integration
I. About the new integrated company 6. Synergies of integration Research and Development • Enhance and widen the product pipeline for gastrointestinal disease field • Strengthen clinical development ability and improve probability of success by combining human resources, know‐how and networks Produc
Slide 11: Positioning of the pharmaceuticals business
II. Purpose of integration for Ajinomoto Co. 1. Positioning of the pharmaceuticals business 1. History of the Ajinomoto Group’s involvement in the pharmaceuticals business • Since the 1981 launch of the pharmaceutical product ELENTAL® featuring amino acid as its primary component, the Ajinomoto Grou
Slide 12: Purpose of integration for Ajinomoto Co.
II. Purpose of integration for Ajinomoto Co. 2. Purpose of integration 1.Strengthen business structure • As a part of the 2014-2016 medium-term plan which features FIT (business structure reform) as a key theme, work to strengthen the business structure through integration with external partners and
Slide 13: Reference materials
Reference materials
Slide 14: Outline of Ajinomoto Pharmaceuticals Co., Ltd.
Outline of AJINOMOTO PHARMACEUTICALS CO., LTD. 1. Location: 2-1-1, Irifune, Chuo-ku, Tokyo, Japan 2. Inauguration: April 1, 2010 3. Major shareholders: Ajinomoto Co., Inc. (100%) 4. Capital: JPY 4,650 million 5. Representative: Representative Director, President and CEO Takashi Nagamachi 6. Scope of
Slide 15: Outline of Eisai's business to be split off
Outline of Eisai’s business to be split off The portion of the business being split off via the absorption-type split are the domestic marketing and R&D functions of Eisai’s gastrointestinal disease business 1. Products and pipeline products to be transferred to the succeeding company: Product/ Expl
Slide 16: Eisai's gastrointestinal disease business assets
Eisai’s gastrointestinal disease business assets 1. Potent product lineup Pariet Rabecure Pack Rabefine Pack Selbex Stronger Neo-Minophagen C Glycyron LipaCreon Glucagon G Novo 2. Promising pipeline E3810 (expanded indication for Pariet, Phase III in Japan) E6011 (anti-fractalkine antibody [Crohn’s
Slide 17: Eat Well, Live Well.
Eat Well, Live Well. AYINOMOTO. ~